Back to results
US 10,881,665 B2Granted
Formulations for treatment of post-traumatic stress disorder
AssigneeGlytech, Inc.
InventorDaniel C. Javitt
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions for reducing symptoms of post-traumatic stress disorder. The compositions include a combination of an N-methyl-D-aspartate (NMDA) receptor antagonist and an anti-depression agent.
Claims10
A method for treatment of post-traumatic stress disorder, (PTSD), or the symptoms thereof, comprising:
- parenterally administering ketamine to a subject in need thereof, followed by administering to the subject a pharmaceutical formulation comprising:
- D-cycloserine administered at a dosage of ≥500 mg/d to ≤1000 mg/d, and formulated to produce blood levels in excess of 25 microgram (μg)/mL, and
- an anti-depression or anti-psychosis agent,
- thereby treating the PTSD, or symptoms thereof.
1 more element
Dependencies are inferred from the claim text.